Vitamin D in cancer chemoprevention

References

• Abe E, Miyaura C, Sakagami H, et al. (2004). Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 78:4990–4
   Google Scholar
• Abe-Hashimoto J, Kikuchi T, Matsumoto T, et al. (1993). Antitumor effect of 22-oxa-calcitriol, a noncalcemic analogue of calcitriol, in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen. Cancer Res 53:2534–7
   PubMed Web of Science ®Google Scholar
• Abe J, Nakano T, Nishii Y, et al. (1991). A novel vitamin D3 analog, 22-oxa-1,25-dihydroxyvitamin D3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia. Endocrinology 129:832–7
   PubMed Web of Science ®Google Scholar
• Adorini L, Penna G, Amuchastegui S, et al. (2007). Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol). J Steroid Biochem 103:689–93
   Google Scholar
• Aggarwal BB. (2004). Nuclear factor-kappaB: The enemy within. Cancer Cell 6:203–8
   PubMed Web of Science ®Google Scholar
• Agoston ES, Hatcher MA, Kensler TW, Posner GH. (2006). Vitamin D analogs as anti-carcinogenic agents. Anticancer Agents Med Chem 6:53–71
   PubMedGoogle Scholar
• Ajibade AA, Kirk JS, Karasik E, et al. (2014). Early growth inhibition is followed by increased metastatic disease with vitamin D (calcitriol) treatment in the TRAMP model of prostate cancer. PLoS One 9:e89555
   Google Scholar
• Akhter J, Chen X, Bowrey P, et al. (1997). Vitamin D3 analog, EB1089, inhibits growth of subcutaneous xenografts of the human colon cancer cell line, LoVo, in a nude mouse model. Dis Colon Rectum 40:317–21
   PubMedGoogle Scholar
• Akiyama N, Miyazawa K, Kanda Y, et al. (2010). Multicenter phase II trial of vitamin K(2) monotherapy and vitamin K(2) plus 1alpha-hydroxyvitamin D(3) combination therapy for low-risk myelodysplastic syndromes. Leuk Res 34:1151–7
   PubMedGoogle Scholar
• Al-Jaderi Z, Maghazachi AA. (2013). Effects of vitamin D3, calcipotriol and FTY720 on the expression of surface molecules and cytolytic activities of human natural killer cells and dendritic cells. Toxins (Basel) 5:1932–47
   PubMed Web of Science ®Google Scholar
• An BS, Tavera-Mendoza LE, Dimitrov V, et al. (2010). Stimulation of Sirt1-regulated FoxO protein function by the ligand-bound vitamin D receptor. Mol Cell Biol 30:4890–900
   PubMed Web of Science ®Google Scholar
• Anderson LN, Cotterchio M, Vieth R, Knight JA. (2010). Vitamin D and calcium intakes and breast cancer risk in pre- and postmenopausal women. Am J Clin Nutr 91:1699–707
   PubMed Web of Science ®Google Scholar
• Anderson MG, Nakane M, Ruan X, et al. (2006). Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemoth Pharm 57:234–40
   PubMed Web of Science ®Google Scholar
• Aparna R, Subhashini J, Roy KR, et al. (2008). Selective inhibition of cyclooxygenase-2 (COX-2) by 1alpha,25-dihydroxy-16-ene-23-yne vitamin D3, a less calcemic vitamin D analog. J Cell Biochem 104:1832–42
   PubMedGoogle Scholar
• Arai MA, Kittaka A. (2006). Novel 2-alkyl-1alpha,25-dihydroxy-19-norvitamin D3: Efficient synthesis with Julia olefination, evaluation of biological activity and development of new analyzing system for co-activator recruitment. Anticancer Res 26:2621–31
   PubMedGoogle Scholar
• Arai MA, Takeyama K, Ito S, et al. (2007). High-throughput system for analyzing ligand-induced cofactor recruitment by vitamin D receptor. Bioconjug Chem 18:614–20
   PubMedGoogle Scholar
• Armas LA, Dowell S, Akhter M, et al. (2007). Ultraviolet-B radiation increases serum 25-hydroxyvitamin D levels: The effect of UVB dose and skin color. J Am Acad Dermatol 57:588–93
   PubMed Web of Science ®Google Scholar
• Baldwin AS. (2012). Regulation of cell death and autophagy by IKK and NF-κB: Critical mechanisms in immune function and cancer. Immunol Rev 246:327–45
   PubMed Web of Science ®Google Scholar
• Banakar MC, Paramasivan SK, Chattopadhyay MB, et al. (2004). 1Alpha,25-dihydroxyvitamin D3 prevents DNA damage and restores antioxidant enzymes in rat hepatocarcinogenesis induced by diethylnitrosamine and promoted by phenobarbital. World J Gastroenterol 10:1268–75
   PubMed Web of Science ®Google Scholar
• Bao BY, Ting HJ, Hsu JW, Lee YF. (2008). Protective role of 1 alpha,25-dihydroxyvitamin D3 against oxidative stress in nonmalignant human prostate epithelial cells. Int J Cancer 122:2699–706
   PubMed Web of Science ®Google Scholar
• Bao BY, Ting HJ, Hsu JW, et al. (2010). Down-regulation of NF-kappaB signals is involved in loss of 1alpha,25-dihydroxyvitamin D3 responsiveness. J Steroid Biochem Mol Biol 120:11–21
   PubMedGoogle Scholar
• Bao BY, Yao J, Lee YF. (2006). 1Alpha,25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis 27:1883–93
   PubMed Web of Science ®Google Scholar
• Beer TM, Ryan CW, Venner PM; ASCENT (AIPC Study of Calcitriol ENhancing Taxotere) Investigators, et al. (2008). Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: Results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. Cancer 112:326–30
   PubMed Web of Science ®Google Scholar
• Beildeck ME, Islam M, Shah S, et al. (2009). Control of TCF-4 expression by VDR and vitamin D in the mouse mammary gland and colorectal cancer cell lines. PLoS One 4:e7872
   Google Scholar
• Ben-Shoshan M, Amir S, Dang DT, et al. (2007). 1 Alpha,25 dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells. Mol Cancer Ther 6:1433–9
   PubMed Web of Science ®Google Scholar
• Berkovic L, Ben-Shabat S, Sintov AC. (2010). Induction of apoptosis and inhibition of prostate and breast cancer growth by BGP-15, a new calcipotriene-derived vitamin D3 analog. Anticancer Drugs 21:609–18
   PubMedGoogle Scholar
• Bernardi RJ, Johnson CS, Modzelewski RA, Trump DL. (2002). Antiproliferative effects of 1alpha,25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells. Endocrinology 143:2508–14
   PubMed Web of Science ®Google Scholar
• Bertone-Johnson ER, Chen WY, Holick MF, et al. (2005). Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidem Biomarkers Prev 14:1991–7
   PubMed Web of Science ®Google Scholar
• Bessler H, Djaldetti M. (2012). 1α,25-Dihydroxyvitamin D3 modulates the interaction between immune and colon cancer cells. Biomed Pharmacother 66:428–32
   PubMedGoogle Scholar
• Bettoun DJ, Buck DW, Lu J, et al. (2002). A vitamin D receptor-Ser/Thr phosphatase-p70 S6 kinase complex and modulation of its enzymatic activities by the ligand. J Biol Chem 277:24847–50
   PubMed Web of Science ®Google Scholar
• Bhatia M, Kirkland JB, Meckling-Gill KA. (1995). Monocytic differentiation of acute promyelocytic leukemia cells in response to 1,25-dihydroxyvitamin D3 is independent of nuclear receptor binding. J Biol Chem 270:15962–5
   PubMedGoogle Scholar
• Bhatia M, Kirkland JB, Meckling-Gill KA. (1996). 1,25-dihydroxyvitamin D3 primes acute promyelocytic cells for TPA-induced monocytic differentiation through both PKC and tyrosine phosphorylation cascades. Exp Cell Res 222:61–9
   PubMedGoogle Scholar
• Bhatia V, Saini MK, Shen X, et al. (2009). EB1089 inhibits the parathyroid hormone-related protein enhanced bone metastasis and xenograft growth of human prostate cancer cells. Mol Cancer Ther 8:1787–98
   PubMedGoogle Scholar
• Bikle DD. (2012). Vitamin D and the skin: Physiology and pathophysiology. Rev Endocr Metab Disord 13:3–19
   Google Scholar
• Binderup L, Bramm E. (1988). Effects of a novel vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo. Biochem Pharmacol 37:889–95
   PubMed Web of Science ®Google Scholar
• Binderup L, Latini S, Binderup E, et al. (1991). 20-Epi-vitamin D3 analogues: A novel class of potent regulators of cell growth and immune responses. Biochem Pharmacol 42:1569–75
   PubMed Web of Science ®Google Scholar
• Bizzarri M, Cucina A, Valente MG, et al. (2003). Melatonin and vitamin D3 increase TGF-beta1 release and induce growth inhibition in breast cancer cell cultures. J Surg Res 110:332–7
   PubMed Web of Science ®Google Scholar
• Blomberg Jensen M, Andersen CB, Nielsen JE, et al. (2010). Expression of the vitamin D receptor, 25-hydroxylases, 1alpha-hydroxylase and 24-hydroxylase in the human kidney and renal clear cell cancer. J Steroid Biochem Mol Biol 121:376–82
   PubMed Web of Science ®Google Scholar
• Blutt SE, McDonnell TJ, Polek TC, Weigel NL. (2000). Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology 141:10–17
   PubMed Web of Science ®Google Scholar
• Bogh MK, Schmedes AV, Philipsen PA, et al. (2010). Vitamin D production after UVB exposure depends on baseline vitamin D and total cholesterol but not on skin pigmentation. J Invest Dermatol 130:546–53
   PubMed Web of Science ®Google Scholar
• Bouillon R, Carmeliet G, Verlinden L, et al. (2008). Vitamin D and human health: Lessons from vitamin D receptor null mice. Endocr Rev 29:726–76
   PubMed Web of Science ®Google Scholar
• Bower M, Colston KW, Stein RC, et al. (1991). Topical calcipotriol treatment in advanced breast cancer. Lancet 337:701–2
   PubMed Web of Science ®Google Scholar
• Boyle BJ, Zhao XY, Cohen P, Feldman D. (2001). Insulin-like growth factor binding protein-3 mediates 1 alpha,25-dihydroxyvitamin D(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J Urol 165:1319–24
   PubMed Web of Science ®Google Scholar
• Brown AJ, Slatopolsky E. (2008). Vitamin D analogs: Therapeutic applications and mechanisms for selectivity. Mol Aspects Med 29:433–52
   PubMed Web of Science ®Google Scholar
• Brozek W, Manhardt T, Kállay E, et al. (2012). Relative expression of vitamin D hydroxylases, CYP27B1 and CYP24A1, and of cyclooxygenase-2 and heterogeneity of human colorectal cancer in relation to age, gender, tumor location, and malignancy: Results from factor and cluster analysis. Cancers (Basel) 4:763–76
   PubMedGoogle Scholar
• Brożyna AA, Jozwicki W, Janjetovic Z, Slominski AT. (2011). Expression of vitamin D receptor decreases during progression of pigmented skin lesions. Hum Pathol 42:618–31
   PubMedGoogle Scholar
• Byers SW, Rowlands T, Beildeck M, Bong YS. (2012). Mechanism of action of vitamin D and the vitamin D receptor in colorectal cancer prevention and treatment. Rev Endocr Metab Disord 13:31–8
   Google Scholar
• Byrne B, Welsh J. (2007). Identification of novel mediators of Vitamin D signaling and 1,25(OH)2D3 resistance in mammary cells. J Steroid Biochem Mol Biol 103:703–7
   PubMed Web of Science ®Google Scholar
• Campbell MJ, Gombart AF, Kwok SH, et al. (2000). The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression. Oncogene 19:5091–7
   PubMed Web of Science ®Google Scholar
• Cantorna MT. (2012). Vitamin D, multiple sclerosis and inflammatory bowel disease. Arch Biochem Biophys 523:103–6
   PubMed Web of Science ®Google Scholar
• Cao X, Ross FP, Zhang L, et al. (1993). Cloning of the promoter for the avian integrin beta 3 subunit gene and its regulation by 1,25-dihydroxyvitamin D3. J Biol Chem 268:27371–80
   PubMed Web of Science ®Google Scholar
• Cardús A, Parisi E, Gallego C, et al. (2006). 1,25-Dihydroxyvitamin D3 stimulates vascular smooth muscle cell proliferation through a VEGF-mediated pathway. Kidney Int 69:1377–84
   PubMed Web of Science ®Google Scholar
• Chan AT, Giovannucci EL. (2010). Primary prevention of colorectal cancer. Gastroenterology 138:2029–43
   PubMed Web of Science ®Google Scholar
• Chaudhry M, Sundaram S, Gennings C, et al. (2001). The vitamin D3 analog, ILX-23-7553, enhances the response to adriamycin and irradiation in MCF-7 breast tumor cells. Cancer Chemother Pharmacol 47:429–36
   Google Scholar
• Chen A, Davis BH, Sitrin MD, et al. (2002). Transforming growth factor-beta 1 signaling contributes to Caco-2 cell growth inhibition induced by 1,25(OH)2D3. Am J Physiol Gastrointest Liver Physiol 283:864–74
   PubMed Web of Science ®Google Scholar
• Chen TC, Holick MF. (2003). Vitamin D and prostate cancer prevention and treatment. Trends Endocrinol Metab 14:423–30
   PubMed Web of Science ®Google Scholar
• Chen TC, Holick MF, Lokeshwar BL, et al. (2003). Evaluation of vitamin D analogs as therapeutic agents for prostate cancer. Recent Res Cancer 164:273–88
   PubMedGoogle Scholar
• Chen TC, Kittaka A. (2011). Novel vitamin D analogs for prostate cancer therapy. ISRN Urolol 2011:301490. doi:10.5402/2011/301490
   Google Scholar
• Chen TC, Sakaki T, Yamamoto K, Kittaka A. (2012). The roles of cytochrome P450 enzymes in prostate cancer development and treatment. Anticancer Res 32:291–8
   PubMed Web of Science ®Google Scholar
• Chiang KC, Yeh CN, Chen SC, et al. (2012). MART-10, a new generation of vitamin D analog, is more potent than 1α,25-dihydroxyvitamin D(3) in inhibiting cell proliferation and inducing apoptosis in ER+ MCF-7 breast cancer cells. Evid Based Complement Alternat Med, 2012:310872. doi: 10.1155/2012/310872
   Google Scholar
• Chiang KC, Chen SC, Yeh CN, et al. (2014). MART-10, a less calcemic vitamin D analog, is more potent than 1α,25-dihydroxyvitamin D3 in inhibiting the metastatic potential of MCF-7 breast cancer cells in vitro. Steroid Biochem Mol Biol 139:54–60
   PubMedGoogle Scholar
• Cho KH, Son YS, Lee DY, et al. (1996). Calcipotriol (MC 903), a synthetic derivative of vitamin D3 stimulates differentiation of squamous carcinoma cell line in the raft culture. Anticancer Res 16:337–47
   PubMedGoogle Scholar
• Choi M, Makishima M. (2009). Therapeutic applications for novel non-hypercalcemic vitamin D receptor ligands. Expert Opin Ther Pathol 19:593–606
   PubMed Web of Science ®Google Scholar
• Chung I, Han G, Seshadri M, et al. (2009). Role of vitamin D receptor in the antiproliferative effects of calcitriol intumor-derived endothelial cells and tumor angiogenesis in vivo. Cancer Res 69:967–75
   PubMed Web of Science ®Google Scholar
• Chung I, Wong MK, Flynn G, et al. (2006). Differential antiproliferative effects of calcitriol on tumor-derived and matrigel-derived endothelial cells. Cancer Res 66:8565–73
   PubMed Web of Science ®Google Scholar
• Cianferotti L, Cox M, Skorija K, Demay MB. (2007). Vitamin D receptor is essential for normal keratinocyte stem cell function. Proc Natl Acad Sci USA 104:9428–33
   PubMed Web of Science ®Google Scholar
• Circu ML, Aw TY. (2010). Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med 48:749–62
   PubMed Web of Science ®Google Scholar
• Clinckspoor I, Hauben E, Verlinden L, et al. (2012). Altered expression of key players in vitamin D metabolism and signaling in malignant and benign thyroid tumors. J Histochem Cytochem 60:502–11
   PubMedGoogle Scholar
• Colston K, Colston MJ, Feldman D. (1981). 1,25-Dihydroxyvitamin D3 and malignant melanoma: The presence of receptors and inhibition of cell growth in culture. Endocrinology 108:1083–6
   PubMed Web of Science ®Google Scholar
• Colston KW, Chander SK, Mackay AG, Coombes RC. (1992). Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol 44:693–702
   PubMed Web of Science ®Google Scholar
• Colston KW, Mackay AG, James SY, et al. (1992a). EB1089: A new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro. Biochem Pharmacol 44:2273–80
   PubMed Web of Science ®Google Scholar
• Colston KW, Perks CM, Xie SP, Holly JM. (1998). Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like growth factor binding protein-3. J Mol Endocrinol 20:157–62
   PubMedGoogle Scholar
• Colston KW, Hansen CM. (2002). Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocr Relat Cancer 9:45–59
   PubMed Web of Science ®Google Scholar
• Cordes T, Hoellen, Dittmer C, et al. (2012). Correlation of prostaglandin metabolizing enzymes and serum PGE2 levels with vitamin D receptor and serum 25 (OH) 2D3 levels in breast and ovarian cancer. Anticancer Res 32:351–7
   PubMedGoogle Scholar
• Crescioli C, Villari D, Forti G, et al. (2002). Des (1-3) IGF-I-stimulated growth of human stromal BPH cells is inhibited by a vitamin D3 analogue. Mol Cell Endocrinol 198:69–75
   PubMedGoogle Scholar
• Cross HS, Bises G, Lechner D, et al. (2005). The vitamin D endocrine system of the gut – Its possible role in colorectal cancer prevention. J Steroid Biochem Mol Biol 97:121–8
   PubMedGoogle Scholar
• Cross HS, Nittke T, Kallay E. (2011). Colonic vitamin D metabolism: Implications for the pathogenesis of inflammatory bowel disease and colorectal cancer. Mol Cell Endocrinol 347:70–9
   PubMed Web of Science ®Google Scholar
• Cross HS, Nittke T, Peterlik M. (2009). Modulation of vitamin D synthesis and catabolism in colorectal mucosa: A new target for cancer prevention. Anticancer Res 29:3705–12
   PubMedGoogle Scholar
• Cunningham D, Gilchrist NL, Cowan RA, et al. (1985). Alfacalcidol as a modulator of growth of low grade non-Hodgkin's lymphomas. Br Med J (Clin Res Ed) 291:1153–5
   PubMedGoogle Scholar
• Dalhoff K, Dancey J, Astrup L, et al. (2003). A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. Br J Cancer 89:252–7
   PubMed Web of Science ®Google Scholar
• Dalirsani Z, Farajnia S, Javadzadeh Y, et al. (2012). The effects of 5-fluorouracil alone and in combination with 13-cis retinoic acid and vitamin D3 on human oral squamous cell carcinoma lines. J Contemp Dent Pract 13:345–50
   PubMedGoogle Scholar
• Daniel C, Schroder O, Zahn N, et al. (2007). The TGF beta/Smad 3-signaling pathway is involved in butyrate-mediated vitamin D receptor (VDR)-expression. J Cell Biochem 102:1420–31
   PubMedGoogle Scholar
• Danielsson C, Fehsel K, Polly P, Carlberg C. (1998). Differential apoptotic response of human melanoma cells to 1 alpha,25-dihydroxyvitamin D3 and its analogues. Cell Death Differ 5:946–52
   PubMed Web of Science ®Google Scholar
• Davis JS, Wu X. (2012). Current state and future challenges of chemoprevention. Discov Med 13:385–90
   PubMedGoogle Scholar
• Deeb KK, Trump DL, Johnson CS. (2007). Vitamin D signalling pathways in cancer: Potential for anticancer therapeutics. Nat Rev Cancer 7:684–700
   Google Scholar
• Demasters G, Di X, Newsham I, et al. (2006). Potentiation of radiation sensitivity in breast tumor cells by the vitamin D3 analogue, EB1089, through promotion of autophagy and interference with proliferative recovery. Mol Cancer Ther 5:2786–97
   PubMed Web of Science ®Google Scholar
• Díaz GD, Paraskeva C, Thomas MG, et al. (2000). Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: Possible implications for prevention and therapy. Cancer Res 60:2304–12
   PubMed Web of Science ®Google Scholar
• Di Cunto F, Topley G, Calautti E, et al. (1998). Inhibitory function of p21Cip1/WAF1 in differentiation of primary mouse keratinocytes independent of cell cycle control. Science 280:1069–72
   PubMed Web of Science ®Google Scholar
• Drivdahl RH, Loop SM, Andress DL, Ostenson RC. (1995). IGF-binding proteins in human prostate tumor cells: Expression and regulation by 1,25-dihydroxyvitamin D3. Prostate 26:72–9
   PubMedGoogle Scholar
• Dröge W. (2003). Autophagy and aging – Importance of amino acid levels. Mech Ageing Dev 225:161–8
   Google Scholar
• Edfeldt K, Liu PT, Chun R, et al. (2010). T-cell cytokines differentially control human monocyte antimicrobial responses by regulating vitamin D metabolism. Proc Natl Acad Sci USA 107:22593–8
   PubMed Web of Science ®Google Scholar
• Eide MJ, Johnson DA, Jacobsen GR, et al. (2011). Vitamin D and nonmelanoma skin cancer in a health maintenance organization cohort. Arch Dermatol 147:1379–84
   Google Scholar
• Elstner E, Campbell MJ, Munker R, et al. (1999). Novel 20-epi-vitamin D3 analog combined with 9-cis-retinoic acid markedly inhibits colony growth of prostate cancer cells. Prostate 40:141–9
   PubMed Web of Science ®Google Scholar
• Engel P, Fagherazzi G, Boutten A, et al. (2010). Serum 25(OH) vitamin D and risk of breast cancer: A nested case-control study from the French E3N cohort. Cancer Epidemiol Biomarkers Prev 19:2341–50
   PubMed Web of Science ®Google Scholar
• Engeset D, Alsaker E, Lund E, et al. (2006). Fish consumption and breast cancer risk. The European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 119:175–82
   PubMed Web of Science ®Google Scholar
• Escaleira MT, Brentani MM. (1999). Vitamin D3 receptor (VDR) expression in HC-11 mammary cells: Regulation by growth-modulatory agents, differentiation, and Ha-ras transformation. Breast Cancer Res Treat 54:123–33
   PubMedGoogle Scholar
• Evans TR, Colston KW, Lofts FJ, et al. (2002). A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer. Br J Cancer 86:680–5
   PubMed Web of Science ®Google Scholar
• Fedirko V, Bostick RM, Flanders WD, et al. (2009). Effects of vitamin D and calcium on proliferation and differentiation in normal colon mucosa: A randomized clinical trial. Cancer Epidemiol Biomarkers Prev 18:2933–41
   PubMed Web of Science ®Google Scholar
• Fedirko V, Bostick RM, Long Q, et al. (2010). Effects of supplemental vitamin D and calcium on oxidative DNA damage marker in normal colorectal mucosa: A randomized clinical trial. Cancer Epidemiol Biomarkers Prev 19:280–91
   PubMed Web of Science ®Google Scholar
• Feldman D, Krishnan AV, Swami S, et al. (2014). The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer 14:342–57
   PubMed Web of Science ®Google Scholar
• Fernandez-Garcia NI, Pálmer HG, Garcia M, et al. (2005). 1,25- Dihydroxyvitamin D3 regulates the expression of ld1 and ld2 genes and the angiogenic phenotype of human colon carcinoma cells. Oncogene 24:6533–44
   PubMed Web of Science ®Google Scholar
• Fischer J, Wang TT, Kaldre D, et al. (2012). Synthetically accessible non-secosteroidal hybrid molecules combining vitamin D receptor agonism and histone deacetylase inhibition. Chem Biol 19:963–71
   PubMed Web of Science ®Google Scholar
• Flanagan JN, Zheng S, Chiang KC, et al. (2009). Evaluation of 19-nor-2alpha-(3-hydroxypropyl)-1alpha,25-dihydroxyvitamin D3 as a therapeutic agent for androgen-dependent prostate cancer. Anticancer Res 29:3547–53
   PubMedGoogle Scholar
• Flanagan L, Packman K, Juba B, et al. (2003). Efficacy of Vitamin D compounds to modulate estrogen receptor negative breast cancer growth and invasion. J Steroid Biochem Mol Biol 84:181–92
   PubMed Web of Science ®Google Scholar
• Fleet JC, DeSmet M, Johnson R, Li Y. (2012). Vitamin D and cancer: A review of molecular mechanisms. Biochem J 441:61–76
   PubMed Web of Science ®Google Scholar
• Flores O, Wang Z, Knudsen KE, Burnstein KL. (2010). Nuclear targeting of cyclin-dependent kinase 2 reveals essential roles of cyclin-dependent kinase 2 localization and cyclin E in vitamin D-mediated growth inhibition. Endocrinology 151:896–908
   PubMed Web of Science ®Google Scholar
• Flynn G, Chung I, Yu WD, et al. (2006). Calcitriol (1,25-dihydroxycholecalciferol) selectively inhibits proliferation of freshly isolated tumor-derived endothelial cells and induces apoptosis. Oncology 70:447–57
   PubMed Web of Science ®Google Scholar
• Freedman DM, Looker AC, Chang SC, Graubard BI. (2007). Prospective study of serum vitamin D and cancer mortality in the United States. J Natl Cancer Inst 99:1594–602
   PubMed Web of Science ®Google Scholar
• Friedrich M, Diesing D, Cordes T, et al. (2006). Analysis of 25-hydroxyvitamin D3-1alpha-hydroxylase in normal and malignant breast tissue. Anticancer Res 26:2615–20
   PubMed Web of Science ®Google Scholar
• Fukumoto S. (2014). Phosphate metabolism and vitamin D. Bonekey Rep 3:497. doi:10.1038/bonekey.2013.231
   PubMedGoogle Scholar
• Funato K, Miyazawa K, Yaguchi M, et al. (2002). Combination of 22-oxa-1,25-dihydroxyvitamin D(3), a vitamin D(3) derivative, with vitamin K(2) (VK2) synergistically enhances cell differentiation but suppresses VK2-inducing apoptosis in HL-60 cells. Leukemia 16:1519–27
   PubMed Web of Science ®Google Scholar
• Furigay P, Swamy N. (2004). Anti-endothelial properties of 1,25-dihydroxy-3-epi-vitamin D3, a natural metabolite of calcitriol. J Steroid Biochem Mol Biol 89:427–31
   PubMedGoogle Scholar
• Gandini S, Boniol M, Haukka J, et al. (2011). Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer 128:1414–24
   PubMed Web of Science ®Google Scholar
• Garcia LA, King KK, Ferrini MG, et al. (2011). 1,25(OH)2vitamin D3 stimulates myogenic differentiation by inhibiting cell proliferation and modulating the expression of promyogenic growth factors and myostatin in C2C12 skeletal muscle cells. Endocrinology 152:2976–86
   PubMed Web of Science ®Google Scholar
• Garland CF, Gorham ED, Mohr SB, et al. (2007). Vitamin D and prevention of breast cancer: Pooled analysis. J Steroid Biochem Mol Biol 103:708–11
   PubMed Web of Science ®Google Scholar
• Gaschott T, Steinmeyer A, Steinhilber D, Stein J. (2002). ZK156718 a low calcemic, antiproliferative, and prodifferentiating vitamin D analog. Biochem Biophys Res Commun 290:504–9
   PubMedGoogle Scholar
• Gedlicka C, Hager G, Weissenböck M, et al. (2006). 1,25(OH)2Vitamin D3 induces elevated expression of the cell cycle inhibitor p18 in a squamous cell carcinoma cell line of the head and neck. J Oral Pathol Med 35:472–8
   PubMed Web of Science ®Google Scholar
• Gee J, Bailey H, Kim K, et al. (2013). Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin. Prostate 9:970–8
   Google Scholar
• Geng S, Zhou S, Glowacki J. (2011). Effects of 25-hydroxyvitamin D(3) on proliferation and osteoblast differentiation of human marrow stromal cells require CYP27B1/1α-hydroxylase. J Bone Miner Res 26:1145–53
   PubMed Web of Science ®Google Scholar
• Ghous Z, Akhter J, Pourgholami MH, Morris DL. (2008). Inhibition of hepatocellular cancer by EB1089: In vitro and in vivo study. Anticancer Res 28:3757–61
   PubMed Web of Science ®Google Scholar
• Giardina C, Madigan JP, Tierney CA, et al. (2012). Vitamin D resistance and colon cancer prevention. Carcinogenesis 33:475–82
   PubMedGoogle Scholar
• Gilbert R, Metcalfe C, Fraser WD, et al. (2012). Associations of circulating retinol, vitamin E, and 1,25-dihydroxyvitamin D with prostate cancer diagnosis, stage, and grade. Cancer Causes Control 23:1865–73
   PubMed Web of Science ®Google Scholar
• Giovannucci E. (2010). Epidemiology of vitamin D and colorectal cancer: Casual or causal link?. J Steroid Biochem Mol Biol 121:349–54
   PubMed Web of Science ®Google Scholar
• Gocek E, Studzinski GP. (2009). Vitamin D and differentiation in cancer. Crit Rev Clin Lab Sci 46:190–209
   PubMed Web of Science ®Google Scholar
• Gombart AF, Borregaard N, Koeffler HP. (2005). Human cathelicidin antimicrobical peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J 19:1067–77
   PubMed Web of Science ®Google Scholar
• González-Sancho JM, Larriba MJ, Ordóñez-Morán P, et al. (2006). Effects of 1alpha,25-dihydroxyvitamin D3 in human colon cancer cells. Anticancer Res 26:2669–81
   Google Scholar
• Gonzalo S. (2014). Novel roles of 1α,25(OH)2D3 on DNA repair provide new strategies for breast cancer treatment. J Steroid Biochem Mol Biol 144:59–64
   Google Scholar
• Goodwin PJ, Ennis M, Pritchard KI, et al. (2009). Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol 27:3757–63
   PubMed Web of Science ®Google Scholar
• Gulliford T, English J, Colston KW, et al. (1998). A phase I study of the vitamin D analogue EB1089 in patients with advanced breast and colorectal cancer. Br J Cancer 78:6–13
   PubMedGoogle Scholar
• Gumireddy K, Reddy GS, Ikegaki N, et al. (2003). Anti-proliferative effects of 20-epi-vitamin-D3 analogue, KH1060 in human neuroblastoma: Induction of RAR-beta and p21(Cip1). Cancer Lett 190:51–60
   PubMedGoogle Scholar
• Guzey M, Kitada S, Reed JC. (2002). Apoptosis induction by 1alpha,25-dihydroxyvitamin D3 in prostate cancer. Mol Cancer Ther 1:667–77
   PubMed Web of Science ®Google Scholar
• Hager G, Formanek M, Gedlicka C, et al. (2001). 1,25(OH)2 vitamin D3 induces elevated expression of the cell cycle-regulating genes P21 and P27 in squamous carcinoma cell lines of the head and neck. Acta Otolaryngol 121:103–9
   PubMed Web of Science ®Google Scholar
• Hansen CM, Frandsen TL, Brünner N, Binderup L. (1994). 1 Alpha,25-dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro. Clin Exp Metastasis 12:195–202
   PubMedGoogle Scholar
• Hara K, Kusuzaki K, Takeshita H, et al. (2001). Oral administration of 1alpha hydroxyvitamin D3 inhibits tumor growth and metastasis of a murine osteosarcoma model. Anticancer Res 21:321–4
   PubMedGoogle Scholar
• Harrison JS, Bershadskiy A. (2012). Clinical experience using vitamin D and analogs in the treatment of myelodysplasia and acute myeloid leukemia: A review of the literature. Leuk Res Treatment 2012:125814. doi:10.1155/2012/125814
   Google Scholar
• Hatakeyama S, Yoshino M, Eto K, et al. (2010). Synthesis and preliminary biological evaluation of 20-epi-eldecalcitol [20-epi-1alpha,25-dihydroxy-2beta-(3 hydroxypropoxy)vitamin D3: 20-epi-ED-71]. J Steroid Biochem Mol Biol 121:25–8
   Google Scholar
• Haussler MR, Jurutka PW, Mizwicki M, Norman AW. (2011). Vitamin D receptor (VDR)-mediated actions of 1α,25(H)2 vitamin D3: Genomic and non-genomic mechanisms. Best Pract Res Clin Endocrinol Metab Endocrinol Metab 25:543–59
   PubMed Web of Science ®Google Scholar
• Haussler MR, Whitfield GK, Kaneko I, et al. (2013). Molecular mechanisms of vitamin D action. Calcif Tissue Int 92:77–98
   PubMed Web of Science ®Google Scholar
• Hedlund TE, Moffatt KA, Miller GJ. (1996). Vitamin D receptor expression is required for growth modulation by 1 alpha,25-dihydroxyvitamin D3 in the human prostatic carcinoma cell line ALVA-31. J Steroid Biochem Mol Biol 58:277–88
   PubMedGoogle Scholar
• Hendrickson WK, Flavin R, Kasperzyk JL, et al. (2011). Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. J Clin Oncol 29:2378–85
   PubMedGoogle Scholar
• Henry HL. (2011). Regulation of vitamin D metabolism. Best Pract Res Clin Endocrinol Metab 25:531–41
   PubMed Web of Science ®Google Scholar
• Hershberger PA, Yu WD, Modzelewski RA, et al. (2001). Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res 7:1043–51
   PubMed Web of Science ®Google Scholar
• Hewison M. (2011). Vitamin D and innate and adaptive immunity. Vitam Horm 86:23–62
   PubMed Web of Science ®Google Scholar
• Höbaus J, Thiem U, Hummel DM, Kallay E. (2013). Role of calcium, vitamin D, and the extrarenal vitamin D hydroxylases in carcinogenesis. Anticancer Agents Med Chem 13:20–35
   PubMed Web of Science ®Google Scholar
• Hofer H, Ho Gm, Peterlik M, et al. (1999). Biological effects of 1alpha-hydroxy- and 1beta-(hydroxymethyl)-vitamin D compounds relevant for potential colorectal cancer therapy. J Pharmacol Exp Ther 291:450–5
   PubMedGoogle Scholar
• Holick MF. (2013). Vitamin D. Sunlight and cancer connection. Anticancer Agents Med Chem 13:70–82
   PubMedGoogle Scholar
• Honma Y, Hozumi M, Abe E, et al. (1983). 1 Alpha,25-Dihydroxyvitamin D3 and 1 alpha-hydroxyvitamin D3 prolong survival time of mice inoculated with myeloid leukemia cells. Proc Natl Acad Sci USA 80:201–4
   PubMed Web of Science ®Google Scholar
• Horváth HC, Lakatos P, Kósa JP, et al. (2010). The candidate oncogene CYP24A1: A potential biomarker for colorectal tumorigenesis. J Histochem Cytochem 58:277–85
   PubMedGoogle Scholar
• Høyer-Hansen M, Bastholm L, Mathiasen IS, et al. (2005). Vitamin D analog EB1089 triggers dramatic lysosomal changes and Beclin 1-mediated autophagic cell death. Cell Death Differ 12:1297–309
   PubMed Web of Science ®Google Scholar
• Høyer-Hansen M, Bastholm L, Szyniarowski P, et al. (2007). Control of macroautophagy by calcium, calmodulin-dependent kinase kinase-beta, and Bcl-2. Mol Cell 25:193–205
   PubMed Web of Science ®Google Scholar
• Hoyer-Hansen M, Nordbrandt SP, Jäättelä M. (2010). Autophagy as a basis for the health-promoting effects of vitamin D. Trends Mol Med 16:295–302
   PubMed Web of Science ®Google Scholar
• Hughes PJ, Marcinkowska E, Gocek E, et al. (2010). Vitamin D3-driven signals for myeloid cell differentiation-implications for differentiation therapy. Leuk Res 34:553–65
   PubMed Web of Science ®Google Scholar
• Hsu JW, Yasmin-Karim S, King MR, et al. (2011). Suppression of prostate cancer cell rolling and adhesion to endothelium by 1α,25-dihydroxyvitamin D3. Am J Pathol 178:872–80
   PubMed Web of Science ®Google Scholar
• Hussain T, Gupta S, Mukhtar H. (2003). Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett 191:125–35
   PubMed Web of Science ®Google Scholar
• Huynh H, Pollak M, Zhang JC. (1998). Regulation of insulin-like growth factor (IGF) II and IGF binding protein 3 autocrine loop in human PC-3 prostate cancer cells by vitamin D metabolite 1,25(OH)2D3 and its analog EB1089. Int J Oncol 13:137–43
   PubMedGoogle Scholar
• Iglesias-Gato D, Zheng S, Flanagan JN, et al. (2011). Substitution at carbon 2 of 19-nor-1α,25-dihydroxyvitamin D3 with 3-hydroxypropyl group generates an analogue with enhanced chemotherapeutic potency in PC-3 prostate cancer cells. J Steroid Biochem Mol Biol 127:269–75
   PubMedGoogle Scholar
• Ikeda N, Uemura H, Ishiguro H, et al. (2003). Combination treatment with 1alpha,25-dihydroxyvitamin D3 and 9-cis-retinoic acid directly inhibits human telomerase reverse transcriptase transcription in prostate cancer cells. Mol Cancer Ther 2:739–46
   PubMedGoogle Scholar
• Iino Y, Yoshida M, Sugamata N, et al. (1992). 1-Alpha-hydroxyvitamin D3, hypercalcemia, and growth suppression of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors. Breast Cancer Res Treat 22:133–40
   PubMedGoogle Scholar
• Iseki K, Tatsuta M, Uehara H, et al. (1999). Inhibition of angiogenesis as a mechanism for inhibition by 1alpha-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 of colon carcinogenesis induced by azoxymethane in Wistar rats. Int J Cancer 81:730–3
   PubMed Web of Science ®Google Scholar
• Ishihara J, Inoue M, Iwasaki M, et al. (2008). Dietary calcium, vitamin D, and the risk of colorectal cancer. Am J Clin Nutr 88:1576–83
   PubMed Web of Science ®Google Scholar
• Istfan NW, Person KS, Holick MF, Chen TC. (2007). 1Alpha,25-Dihydroxyvitamin D and fish oil synergistically inhibit G1/S-phase transition in prostate cancer cells. J Steroid Biochem Mol Biol 103:726–30
   PubMed Web of Science ®Google Scholar
• James SY, Williams MA, Newland AC, Colston KW. (1999). Leukemia cell differentiation: Cellular and molecular interactions of retinoids and vitamin D. Gen Pharmacol 32:143–54
   Google Scholar
• Janjetovic Z, Brozyna AA, Tuckey RC, et al. (2011). High basal NF-κB activity in nonpigmented melanoma cells is associated with an enhanced sensitivity to vitamin D3 derivatives. Br J Cancer 105:1874–84
   PubMedGoogle Scholar
• Jäpelt RB, Jakobsen J. (2013). Vitamin D in plants: A review of occurrence, analysis, and biosynthesis. Front Plant Sci 4:136
   PubMed Web of Science ®Google Scholar
• Jenab M, Bueno-de-Mesquita HB, Ferrari P, et al. (2010). Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations: A nested case-control study. Biochem Med J 340:b5500
   Google Scholar
• Jensen SS, Madsen MW, Lukas J, et al. (2001). Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol Endocrinol 15:1370–80
   PubMed Web of Science ®Google Scholar
• Jiang F, Li P, Fornace AJ Jr, et al. (2003a). G2/M arrest by 1,25-dihydroxyvitamin D3 in ovarian cancer cells mediated through the induction of GADD45 via an exonic enhancer. J Biol Chem 278:48030–40
   PubMed Web of Science ®Google Scholar
• Jiang F, Robin AM, Katakowski M, et al. (2003b). Photodynamic therapy with photofrin in combination with buthionine sulfoximine (BSO) of human glioma in the nude rat. Lasers Med Sci 18:128–33
   PubMed Web of Science ®Google Scholar
• John EM, Schwartz GG, Koo J, et al. (2007). Sun exposure, vitamin D receptor gene polymorphisms, and breast cancer risk in a multiethnic population. Am J Epidemiol 166:1409–19
   PubMed Web of Science ®Google Scholar
• Jones G, Prosser DE, Kaufmann M. (2012). 25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): Its important role in the degradation of vitamin D. Arch Biochem Biophys 523:9–18
   PubMed Web of Science ®Google Scholar
• Jones G, Prosser DE, Kaufmann M. (2014). Cytochrome P450-mediated metabolism of vitamin D. J Lipid Res 55:13–31
   PubMed Web of Science ®Google Scholar
• Kasiappan R, Shen Z, Tse AK, et al. (2012). 1,25-Dihydroxyvitamin D3 suppresses telomerase expression and human cancer growth through MicroRNA-498. J Biol Chem 287:41297–309
   PubMedGoogle Scholar
• Kawa S, Yoshizawa K, Nikaido T, Kiyosawa K. (2005). Inhibitory effect of 22-oxa-1,25-dihydroxyvitamin D3, maxacalcitol, on the proliferation of pancreatic cancer cell lines. Steroid Biochem Mol Biol 97:173–7
   PubMedGoogle Scholar
• Ke HZ, Qi H, Crawford DT, et al. (2005). A new vitamin D analog, 2MD, restores trabecular and cortical bone mass and strength in ovariectomized rats with established osteopenia. J Bone Miner Res 20:1742–55
   PubMedGoogle Scholar
• Kemmis CM, Welsh J. (2008). Mammary epithelial cell transformation is associated with deregulation of the vitamin D pathway. J Cell Biochem 105:980–8
   PubMed Web of Science ®Google Scholar
• Khan QJ, Kimler BF, Fabian CJ. (2010). The relationship between vitamin D and breast cancer incidence and natural history. Curr Oncol Rep 12:136–42
   Google Scholar
• Kikuchi H, Murakami S, Suzuki S, et al. (2007). Chemopreventive effect of a vitamin D(3) analog, alfacalcidol, on colorectal carcinogenesis in mice with ulcerative colitis. Anticancer Drugs 18:1183–7
   PubMedGoogle Scholar
• Kim J, Lim SY, Shin A, et al. (2009). Fatty fish and fish omega-3 fatty acid intakes decrease the breast cancer risk: A case-control study. BMC Cancer 9:216
   PubMed Web of Science ®Google Scholar
• Kim M, Mirandola L, Pandey A, et al. (2012). Application of vitamin D and derivatives in hematological malignancies. Cancer Lett 319:8–22
   PubMedGoogle Scholar
• Kissmeyer AM, Binderup L. (1991). Calcipotriol (MC 903): Pharmacokinetics in rats and biological activities of metabolites. A comparative study with 1,25(OH)2D3. Biochem Pharmacol 41:1601–6
   PubMedGoogle Scholar
• Kittaka A, Yoshida A, Chiang KC, et al. (2012). Potent 19-norvitamin D analogs for prostate and liver cancer therapy. Future Med Chem 4:2049–65
   Google Scholar
• Knight JA, Lesosky M, Barnett H, et al. (2007). Vitamin D and reduced risk of breast cancer: A population-based case control study. Cancer Epidem Biomarkers Prev 16:422–9
   PubMed Web of Science ®Google Scholar
• Koli K, Keski-Oja J. (1995). 1,25-Dihydroxyvitamin D3 enhances the expression of transforming growth factor beta 1 and its latent form binding protein in cultured breast carcinoma cells. Cancer Res 55:1540–6
   PubMed Web of Science ®Google Scholar
• Komagata S, Nakajima M, Takagi S, et al. (2009). Human CYP24 catalyzing the inactivation of calcitriol is post-transcriptionally regulated by miR-125b. Mol Pharmacol 76:702–9
   PubMed Web of Science ®Google Scholar
• Koshizuka K, Koike M, Asou H, et al. (1999). Combined effect of vitamin D3 analogs and paclitaxel on the growth of MCF-7 breast cancer cells in vivo. Breast Cancer Res Treat 53:113–20
   Google Scholar
• Kovalenko PL, Zhang Z, Cui M, et al. (2010). 1,25-Dihydroxyvitamin D-mediated orchestration of anticancer, transcript-level effects in the immortalized, non-transformed prostate epithelial cell line, RWPE1. BMC Genomics 11:26
   PubMed Web of Science ®Google Scholar
• Kriebitzsch C, Verlinden L, Eelen G, et al. (2009). The impact of 1,25(OH)2D3 and its structural analogs on gene expression in cancer cells: A microarray approach. Anticancer Res 29:3471–83
   PubMed Web of Science ®Google Scholar
• Krill D, DeFlavia P, Dhir R, et al. (2001). Expression patterns of vitamin D receptor in human prostate. J Cell Biochem 82:566–72
   PubMedGoogle Scholar
• Krishnan AV, Feldman D. (2010). Molecular pathways mediating the anti-inflammatory effects of calcitriol: Implications for prostate cancer chemoprevention and treatment. Endocr Relat Cancer 17:19–38
   PubMedGoogle Scholar
• Krishnan AV, Feldman D. (2011). Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annu Rev Pharmacol Toxicol 10:311–36
   Google Scholar
• Krishnan AV, Moreno J, Nonn L, et al. (2007). Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer. J Steroid Biochem Mol Biol 103:694–702
   PubMed Web of Science ®Google Scholar
• Krishnan AV, Shinghal R, Raghavachari N, et al. (2004). Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays. Prostate 59:243–51
   PubMed Web of Science ®Google Scholar
• Krishnan AV, Swami S, Feldman D. (2012). The potential therapeutic benefits of vitamin D in the treatment of estrogen receptor positive breast cancer. Steroids 77:1107–12
   Google Scholar
• Kristal AR, Till C, Song X, et al. (2014). Plasma vitamin D and prostate cancer risk: Results from the selenium and vitamin E cancer prevention trial. Cancer Epidemiol Biomarkers Prev 23:1494–504
   PubMed Web of Science ®Google Scholar
• Kumagai T, O’Kelly J, Said JW, Koeffler HP. (2003). Vitamin D2 analog 19-nor-1,25-dihydroxyvitamin D2: Antitumor activity against leukemia, myeloma, and colon cancer cells. J Natl Cancer Inst 95:896–905
   PubMed Web of Science ®Google Scholar
• Kumagai T, Shih LY, Hughes SV, et al. (2005). 19-Nor-1,25(OH)2D2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia. Cancer Res 65:2488–97
   PubMedGoogle Scholar
• Kure S, Nosho K, Baba Y, et al. (2009). Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer. Cancer Epidem Biomarkers Prev 18:2765–72
   PubMed Web of Science ®Google Scholar
• Lambert JR, Kelly JA, Shim M, et al. (2006). Prostate derived factor in human prostate cancer cells: Gene induction by vitamin D via a p53-dependent mechanism and inhibition of prostate cancer cell growth. J Cell Physiol 208:566–74
   PubMed Web of Science ®Google Scholar
• Lankelma JM, Voorend DM, Barwari T, et al. (2010). Cathepsin L, target in cancer treatment? Life Sci 86:225–33.
   PubMed Web of Science ®Google Scholar
• Larriba MJ, Muñoz A. (2010). Mechanisms of resistance to vitamin D action in human cancer cells. In: Holick MF, ed. Vitamin D: Physiology, Molecular Biology, and Clinical Applications. New York, NY, USA: Humana Press, 325–33
   Google Scholar
• Larriba MJ, González-Sancho JM, Barbáchano A, et al. (2013). Vitamin D is a multilevel repressor of wnt/b-catenin signaling in cancer cells. Cancers (Basel) 5:1242–60
   PubMedGoogle Scholar
• Lawrence JA, Akman SA, Melin SA, et al. (2013). Oral paricalcitol (19-nor-1,25-dihydroxyvitamin D2) in women receiving chemotherapy for metastatic breast cancer: A feasibility trial. Cancer Biol Ther 14:476–80
   PubMed Web of Science ®Google Scholar
• Lee HJ, Liu H, Goodman C, et al. (2006). Gene expression profiling changes induced by a novel Gemini vitamin D derivative during the progression of breast cancer. Biochem Pharmacol 72:332–43
   PubMedGoogle Scholar
• Lee HJ, Paul S, Atalla N, et al. (2008). Gemini vitamin D analogues inhibit estrogen receptor-positive and estrogen receptor-negative mammary tumorigenesis without hypercalcemic toxicity. Cancer Prev Res 1:1476–84
   Google Scholar
• Lee SJ, Lee YS, Zimmers TA, et al. (2010). Regulation of muscle mass by follistatin and activins. Mol Endocrinol 24:1998–2008
   PubMed Web of Science ®Google Scholar
• Leto G, Sepporta MV, Crescimanno M, et al. (2010). Cathepsin L in metastatic bone disease: Therapeutic implications. Biol Chem 91:655–64
   Google Scholar
• Leyssens C, Verlinden L, Verstuyf A. (2013). Antineoplastic effects of 1,25(OH)2D3 and its analogs in breast, prostate and colorectal cancer. Endocr Relat Cancer 20:R31–47
   Google Scholar
• Leyssens C, Verlinden L, Verstuyf A. (2014). The future of vitamin D analogs. Front Physiol 5:122. doi:10.3389/fphys.2014.00122
   PubMed Web of Science ®Google Scholar
• Li Y, Brown PH. (2009). Prevention of ER-negative breast cancer. Recent Results Cancer Res 181:121–34
   PubMedGoogle Scholar
• Li F, Ling X, Huang H, et al. (2005). Differential regulation of survivin expression and apoptosis by vitamin D3 compounds in two isogenic MCF-7 breast cancer cell sublines. Oncogene 24:1385–95
   PubMedGoogle Scholar
• Liang G, Nan H, Qureshi AA, Han J. (2012). Pre-diagnostic plasma 25-hydroxyvitamin D levels and risk of non-melanoma skin cancer in women. PLoS One 7:e35211
   Google Scholar
• Lin R, Nagai Y, Sladek R, et al. (2002). Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol Endocrinol 16:1243–56
   PubMedGoogle Scholar
• Liu G, Hu X, Chakrabarty S. (2010). Vitamin D mediates its action in human colon carcinoma cells in a calcium-sensing receptor-dependent manner: Downregulates malignant cell behavior and the expression of thymidylate synthase and survivin and promotes cellular sensitivity to 5-FU. Int J Cancer 126:631–9
   PubMedGoogle Scholar
• Lopes N, Sousa B, Martins D, et al. (2010). Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: A study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions Vitamin D pathways unbalanced in breast lesions. BMC Cancer 10:483
   PubMed Web of Science ®Google Scholar
• Lopes N, Carvalho J, Durães C, et al. (2012). 1 Alpha,25-dihydroxyvitamin D3 induces de novo E-cadherin expression in triple-negative breast cancer cells by CDH1-promoter demethylation. Anticancer Res 32:249–57
   PubMed Web of Science ®Google Scholar
• Lowe L, Hansen CM, Senaratne S, Colston KW. (2003). Mechanisms implicated in the growth regulatory effects of vitamin D compounds in breast cancer cells. Results Cancer Res 164:99–110
   PubMedGoogle Scholar
• Lowe LC, Guy M, Mansi JL, et al. (2005). Plasma 25-hydroxyvitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. Eur J Cancer 41:1164–9
   PubMed Web of Science ®Google Scholar
• Lu L, Qiu J, Liu S, Luo W. (2008). Vitamin D3 analogue EB1089 inhibits the proliferation of human laryngeal squamous carcinoma cells via p57. Mol Cancer Ther 7:1268–74
   PubMedGoogle Scholar
• Ma Y, Trump DL, Johnson CS. (2010). Vitamin D in combination cancer treatment. J Cancer 1:101–7
   PubMed Web of Science ®Google Scholar
• Ma Y, Zhang P, Wang F, et al. (2011). Association between vitamin D and risk of colorectal cancer: A systematic review of prospective studies. J Clin Oncol 29:3775–82
   PubMed Web of Science ®Google Scholar
• Ma Y, Yu WD, Hidalgo AA, et al. (2013a). Inecalcitol, an analog of 1,25D3, displays enhanced antitumor activity through the induction of apoptosis in a squamous cell carcinoma model system. Cell Cycle 12:743–52
   PubMed Web of Science ®Google Scholar
• Ma Y, Yu WD, Su B, et al. (2013b). Regulation of motility, invasion, and metastatic potential of squamous cell carcinoma by 1α,25-dihydroxycholecalciferol. Cancer 119:563–74
   PubMedGoogle Scholar
• Maalmi H, Ordóñez-Mena JM, Schöttker B, Brenner H. (2014). Serum 25-hydroxyvitamin D levels and survival in colorectal and breast cancer patients: Systematic review and meta-analysis of prospective cohort studies. Eur J Cancer 50:1510–21
   PubMed Web of Science ®Google Scholar
• Macejová D, Ondková S, Jakubíková L, et al. (2011). MNU-induced mammary gland carcinogenesis: Chemopreventive and therapeutic effects of vitamin D and Seocalcitol on selected regulatory vitamin D receptor pathways. Toxicol Lett 207:60–72
   PubMedGoogle Scholar
• Maier S, Daroqui MC, Scherer S, et al. (2009). Butyrate and vitamin D3 induce transcriptional attenuation at the cyclin D1 locus incolonic carcinoma cells. J Cell Physiol 218:638–42
   PubMedGoogle Scholar
• Maehr H, Rochel N, Lee HJ, et al. (2013). Diastereotopic and deuterium effects in Gemini. J Med Chem 56:3878–88
   PubMed Web of Science ®Google Scholar
• Mäenpää PH, Väisänen S, Jääskeläinen T, et al. (2001). Vitamin D(3) analogs (MC 1288, KH 1060, EB1089, GS1558, and CB1093): Studies on their mechanism of action. Steroids 66:223–5
   PubMed Web of Science ®Google Scholar
• Mantell DJ, Owens PE, Bundred NJ, et al. (2000). 1Alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res 87:214–20
   PubMed Web of Science ®Google Scholar
• Marchiani S, Bonaccorsi L, Ferruzzi P, et al. (2006). The vitamin D analogue BXL-628 inhibits growth factor-stimulated proliferation and invasion of DU145 prostate cancer cells. J Cancer Res Clin Oncol 132:408–16
   PubMed Web of Science ®Google Scholar
• Marotta LL, Almendro V, Marusyk A, et al. (2011). The JAK2/STAT3 signaling pathway is required for growth of CD44–CD24- stem cell-like breast cancer cells in human tumors. J Clin Invest 121:2723–35
   PubMed Web of Science ®Google Scholar
• Maruyama R, Aoki F, Toyota M, et al. (2006). Comparative genome analysis identifies the vitamin D receptor gene as a direct target of p53-mediated transcriptional activation. Cancer Res 66:4574–83
   PubMed Web of Science ®Google Scholar
• Massagué J. (2008). TGF beta in cancer. Cell 134:215–30
   PubMed Web of Science ®Google Scholar
• Massoner P, Colleselli D, Matscheski A, et al. (2009). Novel mechanism of IGF-binding protein-3 action on prostate cancer cells: Inhibition of proliferation, adhesion, and motility. Endocr Relat Cancer 16:795–808
   PubMed Web of Science ®Google Scholar
• Mathiasen IS, Colston KW, Binderup L. (1993). EB1089, a novel vitamin D analogue, has strong antiproliferative and differentiation inducing effects on cancer cells. J Steroid Biochem 46:365–71
   Google Scholar
• Mathiasen IS, Lademann U, Jäättelä M. (1999). Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53. Cancer Res 59:4848–56
   PubMed Web of Science ®Google Scholar
• Matilainen M, Malinen M, Saavalainen K, Carlberg C. (2005). Regulation of multiple insulin-like growth factor binding protein genes by 1alpha,25-dihydroxyvitamin D3. Nucleic Acids Res 33:5521–32
   PubMed Web of Science ®Google Scholar
• Matsumoto H, Iino Y, Koibuchi Y, et al. (1999). Antitumor effect of 22-oxacalcitriol on estrogen receptor-negative MDA-MB-231 tumors in athymic mice. Oncol Rep 6:349–52
   PubMedGoogle Scholar
• Matusiak D, Benya RV. (2007). CYP27A1 and CYP24 expression as a function of malignant transformation in the colon. J Histochem Cytochem 55:1257–64
   PubMedGoogle Scholar
• Matusiak D, Murillo G, Carroll RE, et al. (2005). Expression of vitamin D receptor and 25-hydroxyvitamin D31{alpha}-hydroxylase in normal and malignant human colon. Cancer Epidem Biomarkers Prev 14:2370–6
   PubMed Web of Science ®Google Scholar
• Maund SL, Barclay WW, Hover LD, et al. (2011). Interleukin-1α mediates the antiproliferative effects of 1,25-dihydroxyvitamin D3 in prostate progenitor/stem cells. Cancer Res 71:5276–86
   PubMed Web of Science ®Google Scholar
• McCullough ML, Bostick RM, Mayo TL. (2009). Vitamin D gene pathway polymorphisms and risk of colorectal, breast, and prostate cancer. Annu Rev Nutr 29:111–32
   PubMed Web of Science ®Google Scholar
• Medioni J, Deplanque G, Ferrero JM, et al. (2014). Phase I safety and pharmacodynamic of inecalcitol, a novel VDR agonist with docetaxel in metastatic castration-resistant prostate cancer patients. Clin Cancer Res 20:4471–7
   PubMedGoogle Scholar
• Meeker S, Seamons A, Paik J, et al. (2014). Increased dietary Vitamin D suppresses MAPK signaling, colitis, and colon cancer. Cancer Res 74:4398–408
   PubMed Web of Science ®Google Scholar
• Meephansan J, Komine M, Tsuda H, Ohtsuki M. (2012). Suppressive effect of calcipotriol on the induction of matrix metalloproteinase (MMP)-9 and MMP-13 in a human squamous cell carcinoma cell line. Clin Exp Dermatol 37:889–96
   PubMed Web of Science ®Google Scholar
• Mellibovsky L, Díez A, Pérez-Vila E, et al. (1998). Vitamin D treatment in myelodysplastic syndromes. Br J Haematol 100:516–20
   PubMed Web of Science ®Google Scholar
• Merke J, Milde P, Lewicka S, et al. (1989). Identification and regulation of 1,25-dihydroxyvitamin D3 receptor activity and biosynthesis of 1,25-dihydroxyvitamin D3. Studies in cultured bovine aortic endothelial cells and human dermal capillaries. J Clin Invest 83:1903–15
   PubMed Web of Science ®Google Scholar
• Mehta RG, Peng X, Alimirah F, et al. (2012). Vitamin D and breast cancer: Emerging concepts. Cancer Lett 334:95–100
   PubMedGoogle Scholar
• Milczarek M, Chodyński M, Filip-Psurska B, et al. (2013a). Synthesis and biological activity of diastereomeric and geometric analogs of calcipotriol, PRI-2202 and PRI-2205, against human HL-60 leukemia and MCF-7 breast cancer cells. Cancers (Basel) 5:1355–78
   PubMedGoogle Scholar
• Milczarek M, Psurski M, Kutner A, Wietrzyk J. (2013b). Vitamin D analogs enhance the anticancer activity of 5-fluorouracil in an in vivo mouse colon cancer model. BMC Cancer 13:294
   PubMedGoogle Scholar
• Milczarek M, Rosinska S, Psurski M, et al. (2013c). Combined colonic cancer treatment with vitamin D analogs and irinotecan or oxaliplatin. Anticancer Res 13:433–44
   Google Scholar
• Milczarek M, Filip-Psurska B, Swiętnicki W, et al. (2014). Vitamin D analogs combined with 5-fluorouracil in human HT-29 colon cancer treatment. Oncol Rep 32:491–504
   PubMed Web of Science ®Google Scholar
• Mimori K, Tanaka Y, Yoshinaga K, et al. (2004). Clinical significance of the overexpression of the candidate oncogene CYP24 in esophageal cancer. Ann Oncol 15:236–41
   PubMed Web of Science ®Google Scholar
• Mitschele T, Diesel B, Friedrich M, et al. (2004). Analysis of the vitamin D system in basal cell carcinomas (BCCs). Lab Invest 84:693–702
   Google Scholar
• Mittal MK, Myers JN, Misra S, et al. (2008). In vivo binding to and functional repression of the VDR gene promoter by SLUG in human breast cells. Biochem Biophys Res Commun 372:30–4
   Google Scholar
• Mohr SB, Gorham ED, Alcaraz JE, et al. (2011). Serum 25-hydroxyvitamin D and prevention of breast cancer: Pooled analysis. Anticancer Res 31:2939–48
   Google Scholar
• Molnar I, Kute T, Willingham MC, Schwartz GG. (2004). 19-Nor-1alpha,25-dihydroxyvitamin D2 (paricalcitol) exerts anticancer activity against HL-60 cells in vitro at clinically achievable concentrations. J Steroid Biochem Mol Biol 89–90:539–43
   PubMedGoogle Scholar
• Moreno J, Krishnan AV, Swami S, et al. (2005). Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res 65:7917–25
   PubMed Web of Science ®Google Scholar
• Moreno J, Krishnan AV, Peehl DM, Feldman D. (2006). Mechanisms of vitamin D-mediated growth inhibition in prostate cancer cells: Inhibition of the prostaglandin pathway. Anticancer Res 26:2525–30
   PubMed Web of Science ®Google Scholar
• Mori R, Xiong S, Wang Q, et al. (2009). Gene profiling and pathway analysis of neuroendocrine transdifferentiated prostate cancer cells. Prostate 69:12–23
   PubMed Web of Science ®Google Scholar
• Morselli E, Galluzzi L, Kepp O, et al. (2009). Anti- and pro-tumor functions of autophagy. Biochim Biophys Acta 1793:1524–32
   PubMed Web of Science ®Google Scholar
• Motomura S, Kanamori H, Maruta A, et al. (1991). The effect of 1-hydroxyvitamin D3 for prolongation of leukemic transformation-free survival in myelodysplastic syndromes. Am J Hematol 38:67–8
   PubMed Web of Science ®Google Scholar
• Muindi JR, Nganga A, Engler KL, et al. (2007). CYP24 splicing variants are associated with different patterns of constitutive and calcitriol-inducible CYP24 activity in human prostate cancer cell lines. J Steroid Biochem Mol Biol 103:334–7
   PubMedGoogle Scholar
• Muindi JR, Yu WD, Ma Y, et al. (2010). CYP24A1 inhibition enhances the antitumor activity of calcitriol. Endocrinology 151:4301–12
   PubMed Web of Science ®Google Scholar
• Munetsuna E, Nakabayashi S, Kawanami R, et al. (2011). Mechanism of the anti-proliferative action of 25-hydroxy-19-nor-vitamin D3 in human prostate cells. J Mol Endocrinol 47:209–18
   PubMedGoogle Scholar
• Murthy S, Weigel NL. (2004). 1Alpha,25-dihydroxyvitamin D3 induced growth inhibition of PC-3 prostate cancer cells requires an active transforming growth factor beta signaling pathway. Prostate 59:282–91
   PubMedGoogle Scholar
• Nagpal S, Na S, Rathnachalam R. (2005). Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 26:662–87
   PubMed Web of Science ®Google Scholar
• Nair-Shalliker V, Armstrong BK, Fenech M. (2012). Does vitamin D protect against DNA damage? Mutat Res 733:50–7
   PubMed Web of Science ®Google Scholar
• Nakagawa K, Sasaki Y, Kato S, et al. (2005). 22-Oxa-1alpha,25-dihydroxyvitamin D3 inhibits metastasis and angiogenesis in lung cancer. Carcinogenesis 26:1044–54
   PubMed Web of Science ®Google Scholar
• Nickerson T, Huynh H. (1999). Vitamin D analogue EB1089-induced prostate regression is associated with increased gene expression of insulin-like growth factor binding proteins. J Endocrinol 160:223–9
   PubMedGoogle Scholar
• Nishii Y, Okano T. (2001). History of the development of new vitamin D analogs: Studies on 22-oxacalcitriol (OCT) and 2beta-(3-hydroxypropoxy) calcitriol (ED-71). Steroids 66:137–46
   PubMed Web of Science ®Google Scholar
• Oades GM, Dredge K, Kirby RS, Colston KW. (2002). Vitamin D receptor-dependent antitumour effects of 1,25-dihydroxyvitamin D3 and two synthetic analogues in three in vivo models of prostate cancer. BJU Int 90:607–16
   PubMed Web of Science ®Google Scholar
• Obara W, Mizutani Y, Oyama C, et al. (2008). Prospective study of combined treatment with interferon-alpha and active vitamin D3 for Japanese patients with metastatic renal cell carcinoma. Int J Urol 15:794–9
   PubMedGoogle Scholar
• Oh YS, Kim EJ, Schaffer BS, et al. (2001). Synthetic low-calcaemic vitamin D(3) analogues inhibit secretion of insulin-like growth factor II and stimulate production of insulin-like growth factor-binding protein-6 in conjunction with growth suppression of HT-29 colon cancer cells. Mol Cell Endocrinol 183:141–9
   PubMedGoogle Scholar
• Okamoto R, Gery S, Kuwayama Y, et al. (2014). Novel Gemini vitamin D3 analogs: Large structure/function analysis and ability to induce antimicrobial peptide. Int J Cancer 134:207–17
   PubMedGoogle Scholar
• Okamoto R, Wakimoto N, Doan NB, et al. (2012). Inecalcitol, an analog of 1α,25(OH)(2) D(3) induces growth arrest of androgen-dependent prostate cancer cells. Int J Cancer 130:2464–73
   PubMed Web of Science ®Google Scholar
• Ono K, Yoshida A, Saito N, et al. (2003). Efficient synthesis of 2-modified 1alpha,25-dihydroxy-19-norvitamin D3 with Julia olefination: High potency in induction of differentiation on HL-60 cells. J Org Chem 68:7407–15
   PubMed Web of Science ®Google Scholar
• Otoshi T, Iwata H, Kitano M, et al. (1995). Inhibition of intestinal tumor development in rat multi-organ carcinogenesis and aberrant crypt foci in rat colon carcinogenesis by 22-oxa-calcitriol, a synthetic analogue of 1alpha,25-dihydroxyvitamin D3. Carcinogenesis 16:2091–7
   PubMedGoogle Scholar
• Pala V, Krogh V, Berrino F, et al. (2009). Meat, eggs, dairy products, and risk of breast cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Am J Clin Nutr 90:602–12
   PubMed Web of Science ®Google Scholar
• Pálmer HG, González-Sancho JM, Espada J, et al. (2001). Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol 154:369–87
   PubMed Web of Science ®Google Scholar
• Pálmer HG, Larriba MJ, García JM, et al. (2004). The transcription factor SNAIL represses vitamin D receptor expression and responsiveness in human colon cancer. Nat Med 10:917–19
   PubMed Web of Science ®Google Scholar
• Pálmer HG, Sánchez-Carbayo M, Ordóñez-Morán P, et al. (2003). Genetic signatures of differentiation induced by 1alpha,25-dihydroxyvitamin D3 in human colon cancer cells. Cancer Res 63:7799–806
   PubMed Web of Science ®Google Scholar
• Pan L, Matloob AF, Du J, et al. (2010). Vitamin D stimulates apoptosis in gastric cancer cells in synergy with trichostatin A/sodium butyrate-induced and 5-aza-2′-deoxycytidine-induced PTEN upregulation. FEBS J 277:989–99
   PubMed Web of Science ®Google Scholar
• Park MR, Lee JH, Park MS, et al. (2012). Suppressive effect of 19-nor-1α-25-dihydroxyvitamin D2 on gastric cancer cells and peritoneal metastasis model. J Korean Med Sci 27:1037–43
   PubMedGoogle Scholar
• Peehl DM, Shinghal R, Nonn L, et al. (2004). Molecular activity of 1,25-dihydroxyvitamin D3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis. J Steroid Biochem Mol Biol 92:131–41
   PubMed Web of Science ®Google Scholar
• Pelczynska M, Switalska M, Maciejewska M, et al. (2006). Antiproliferative activity of vitamin D compounds in combination with cytostatics. Anticancer Res 26:2701–5
   PubMedGoogle Scholar
• Peña C, García JM, Silva J, et al. (2005). E-cadherin and vitamin D receptor regulation by SNAIL and ZEB1 in colon cancer: Clinicopathological correlations. Hum Mol Genet 14:3361–70
   PubMed Web of Science ®Google Scholar
• Pendás-Franco N, González-Sancho JM, Suárez Y, et al. (2007). Vitamin D regulates the phenotype of human breast cancer cells. Differentiation 75:193–207
   PubMed Web of Science ®Google Scholar
• Pendás-Franco N, Aguilera O, Pereira F, et al. (2008a). Vitamin D and Wnt/beta-catenin pathway in colon cancer: Role and regulation of DICKKOPF genes. Anticancer Res 28:2613–23
   PubMed Web of Science ®Google Scholar
• Pendás-Franco N, García JM, Peña C, et al. (2008b). DICKKOPF-4 is induced by TCF/beta-catenin and upregulated in human colon cancer, promotes tumour cell invasion and angiogenesis and is repressed by 1alpha,25-dihydroxyvitamin D3. Oncogene 27:4467–77
   PubMed Web of Science ®Google Scholar
• Peng L, Malloy PJ, Feldman D. (2004). Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter. Mol Endocrinol 18:1109–19
   PubMed Web of Science ®Google Scholar
• Peng L, Wang J, Malloy PJ, Feldman D. (2008). The role of insulin-like growth factor binding protein-3 in the growth inhibitory actions of androgens in LNCaP human prostate cancer cells. Int J Cancer 22:558–66
   Google Scholar
• Penna G, Fibbi B, Amuchastegui S, et al. (2009). The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways. Prostate 69:480–93
   PubMed Web of Science ®Google Scholar
• Pereira F, Larriba MJ, Muñoz A. (2012). Vitamin D and colon cancer. Endocr Relat Cancer 19:51–71
   Google Scholar
• Pervin S, Hewison M, Braga M, et al. (2013). Down-regulation of vitamin D receptor in mammospheres: Implications for vitamin D resistance in breast cancer and potential for combination therapy. PLoS One 8:e53287
   PubMed Web of Science ®Google Scholar
• Petrich A, Kahl B, Bailey H, et al. (2008). Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome. Leuk Lymphoma 49:57–6
   Google Scholar
• Pilz S, Kienreich K, Tomaschitz A, et al. (2013). Vitamin D and cancer mortality: Systematic review of prospective epidemiological studies. Anticancer Agents Med Chem 13:107–17
   PubMedGoogle Scholar
• Pirianov G, Colston KW. (2001). Interactions of vitamin D analogue CB1093, TNFalpha and ceramide on breast cancer cell apoptosis. Mol Cell Endocrinol 172:69–78
   PubMedGoogle Scholar
• Plum LA, Fitzpatrick LA, Ma X, et al. (2006). 2MD, a new anabolic agent for osteoporosis treatment. Osteoporos Int 17:704–15
   PubMedGoogle Scholar
• Pommergaard HC, Burcharth J, Rosenberg J, Raskov H. (2013). Combination chemoprevention with diclofenac, calcipotriol and difluoromethylornithine inhibits development of non-melanoma skin cancer in mice. Anticancer Res 33:3033–9
   PubMed Web of Science ®Google Scholar
• Proietti S, Cucina A, D’Anselmi F, et al. (2011). Melatonin and vitamin D3 synergistically down-regulate Akt and MDM2 leading to TGFβ-1-dependent growth inhibition of breast cancer cells. J Pineal Res 50:150–8
   PubMed Web of Science ®Google Scholar
• Reddy KK. (2013). Vitamin D level and basal cell carcinoma, squamous cell carcinoma, and melanoma risk. J Invest Dermatol 133:589–92
   PubMedGoogle Scholar
• Reichrath J, Rafi L, Rech M, et al. (2004). Analysis of the vitamin D system in cutaneous squamous cell carcinomas. J Cutan Pathol 31:224–31
   PubMed Web of Science ®Google Scholar
• Ritter CS, Brown AJ. (2011). Suppression of PTH by the vitamin D analog eldecalcitol is modulated by its high affinity for the serum vitamin D-binding protein and resistance to metabolism. J Cell Biochem 112:1348–52
   PubMed Web of Science ®Google Scholar
• Rollison DE, Cole AL, Tung KH, et al. (2012). Vitamin D intake, vitamin D receptor polymorphisms, and breast cancer risk among women living in the southwestern U.S. Breast Cancer Res Treat 132:683–91
   PubMedGoogle Scholar
• Rook GA, Steele J, Fraher L, et al. (1986). Vitamin D3, gamma interferon, and control of proliferation of mycobacterium tuberculosis by human monocytes. Immunology 57:159–63
   PubMed Web of Science ®Google Scholar
• Rose AA, Elser C, Ennis M, Goodwin PJ. (2013). Blood levels of vitamin D and early stage breast cancer prognosis: A systematic review and meta-analysis. Breast Cancer Res Treat 141:331–9
   PubMed Web of Science ®Google Scholar
• Ross AC, Manson JE, Abrams SA, et al. (2011). The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: What clinicians need to know. J Clin Endocrinol Metab 96:53–8
   PubMed Web of Science ®Google Scholar
• Rossi M, McLaughlin JK, Lagiou P, et al. (2009). Vitamin D intake and breast cancer risk: A case-control study in Italy. Ann Oncol 20:374–8
   PubMed Web of Science ®Google Scholar
• Rots NY, Liu M, Anderson EC, Freedman LP. (1998). A differential screen for ligand-regulated genes: Identification of HoxA10 as a target of vitamin D3 induction in myeloid leukemic cells. Mol Cell Biol 18:1911–18
   PubMedGoogle Scholar
• Roy R, Chun J, Powell SN. (2011). BRCA1 and BRCA2: Different roles in a common pathway of genome protection. Nat Rev Cancer 12:68–78
   PubMed Web of Science ®Google Scholar
• Rozen F, Yang XF, Huynh H, Pollak M. (1997). Antiproliferative action of vitamin D-related compounds and insulin-like growth factor-binding protein 5 accumulation. J Natl Cancer Inst 89:652–6
   PubMedGoogle Scholar
• Ryhänen S, Jääskeläinen T, Mahonen A, Mäenpää PH. (2003). Inhibition of MG-63 cell cycle progression by synthetic vitamin D3 analogs mediated by p27, Cdk2, cyclin E, and the retinoblastoma protein. Biochem Pharmacol 66:495–504
   PubMed Web of Science ®Google Scholar
• Sahin M, Sahin E, Gumuslu S. (2009). Cyclooxygenase-2 in cancer and angiogenesis. Angiology 60:242–53
   PubMed Web of Science ®Google Scholar
• Samuel S, Sitrin MD. (2008). Vitamin D's role in cell proliferation and differentiation. Nutr Rev 66:S116–24
   PubMed Web of Science ®Google Scholar
• Sanford M, McCormack PL. (2011). Eldecalcitol: A review of its use in the treatment of osteoporosis. Drugs 10:1755–70
   Google Scholar
• Sakaki T, Yasuda K, Kittaka A, et al. (2014). CYP24A1 as a potential target for cancer therapy. Anticancer Agents Med Chem 14:97–108
   PubMedGoogle Scholar
• Saunders DE, Christensen C, Wappler NL, et al. (1993). Inhibition of c-myc in breast and ovarian carcinoma cells by 1,25-dihydroxyvitamin D3, retinoic acid and dexamethasone. Anticancer Drugs 4:201–8
   PubMedGoogle Scholar
• Schuster I. (2011). Cytochromes P450 are essential players in the vitamin D signaling system. Biochim Biophys Acta 1814:186–99
   PubMed Web of Science ®Google Scholar
• Schwab M, Reynders V, Loitsch S, et al. (2007). Involvement of different nuclear hormone receptors in butyrate-mediated inhibition of inducible NF kappa B signalling. Mol Immunol 44:3625–32
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Hall MC, Stindt D, et al. (2005). Phase I/II study of 19-nor-1a-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer. Clin Cancer Res 11:8680–5
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Eads D, Naczki C, et al. (2008). 19-nor-1 alpha,25-dihydroxyvitamin D2 (paricalcitol) inhibits the proliferation of human pancreatic cancer cells in vitro and in vivo. Cancer Biol Ther 7:430–6
   PubMed Web of Science ®Google Scholar
• Segersten U, Correa P, Hewison M, et al. (2002). 25-hydroxyvitamin D(3)-1alpha-hydroxylase expression in normal and pathological parathyroid glands. J Clin Endocrinol Metab 87:2967–72
   PubMed Web of Science ®Google Scholar
• Sergeev IN. (2012). Vitamin D and cellular Ca2+ signaling in breast cancer. Anticancer Res 32:299–302
   PubMed Web of Science ®Google Scholar
• Seubwai W, Wongkham C, Puapairoj A, et al. (2010). 22-oxa-1,25-dihydroxyvitamin D3 efficiently inhibits tumor growth in inoculated mice and primary histoculture of cholangiocarcinoma. Cancer 116:5535–43
   PubMedGoogle Scholar
• Shah S, Islam MN, Dakshanamurthy S, et al. (2006). The molecular basis of vitamin D receptor and beta-catenin crossregulation. Mol Cell 21:799–809
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Drake MT, Maurer MJ, et al. (2011). Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. Blood 3:1492–8
   Google Scholar
• Shin MH, Holmes MD, Hankinson SE, et al. (2002). Intake of dairy products, calcium, and vitamin D and risk of breast cancer. J Natl Cancer Inst 94:1301–11
   PubMed Web of Science ®Google Scholar
• Singletary K, Milner J. (2008). Diet, autophagy, and cancer: A review. Cancer Epidemiol Biomarkers Prev 17:1596–610
   PubMed Web of Science ®Google Scholar
• So JY, Lee HJ, Smolarek AK, et al. (2011). A novel Gemini vitamin D analog represses the expression of a stem cell marker CD44 in breast cancer. Mol Pharmacol 79:360–7
   PubMedGoogle Scholar
• So JY, Smolarek AK, Salerno DM, et al. (2013a). Targeting CD44-STAT3 signaling by Gemini vitamin D analog leads to inhibition of invasion in basal-like breast cancer. PLoS One 8:e54020
   PubMed Web of Science ®Google Scholar
• So JY, Wahler JE, Yoon T, et al. (2013b). Oral administration of a gemini vitamin D analog, a synthetic triterpenoid and the combination prevents mammary tumorigenesis driven by ErbB2 overexpression. Cancer Prev Res (Phila) 6:959–70
   PubMedGoogle Scholar
• Solomon C, White JH, Kremer R. (1999). Mitogen-activated protein kinase inhibits 1,25-dihydroxyvitamin D3-dependent signal transduction by phosphorylating human retinoid X receptor alpha. J Clin Invest 103:1729–35
   PubMed Web of Science ®Google Scholar
• Solomon JD, Heitzer MD, Liu TT, et al. (2014). VDR activity is differentially affected by hic-5 in prostate cancer and stromal cells. Mol Cancer Res 12:1166–80
   PubMed Web of Science ®Google Scholar
• Spina CS, Ton L, Yao M, et al. (2007). Selective vitamin D receptor modulators and their effects on colorectal tumor growth. J Steroid Biochem Mol Biol 103:757–62
   PubMedGoogle Scholar
• Sprenger CC, Peterson A, Lance R, et al. (2001). Regulation of proliferation of prostate epithelial cells by 1,25-dihydroxyvitamin D3 is accompanied by an increase in insulin-like growth factor binding protein-3. J Endocrinol 170:609–18
   PubMed Web of Science ®Google Scholar
• Srinivasan M, Parwani AV, Hershberger PA, et al. (2011). Nuclear vitamin D receptor expression is associated with improved survival in non-small cell lung cancer. J Steroid Biochem 123:30–6
   Google Scholar
• Stambolsky P, Tabach Y, Fontemaggi G, et al. (2010). Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell 17:273–85
   PubMed Web of Science ®Google Scholar
• Stewart LMV, Weigel NL. (2004). Vitamin D and prostate cancer. Exp Biol Med 229:4277–84
   Google Scholar
• Stio M, Martinesi M, Simoni A, et al. (2011). The novel vitamin D analog ZK191784 inhibits prostate cancer cell invasion. Anticancer Res 31:4091–8
   PubMedGoogle Scholar
• Stubbs JR, Idiculla A, Slusser J, et al. (2010). Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J Am Soc Nephrol 21:353–61
   PubMed Web of Science ®Google Scholar
• Sundaram S, Chaudhry M, Reardon D, et al. (2000). The vitamin D3 analog EB 1089 enhances the antiproliferative and apoptotic effects of adriamycin in MCF-7 breast tumor cells. Breast Cancer Res Treat 63:1–10
   PubMed Web of Science ®Google Scholar
• Sundaram S, Sea A, Feldman S, et al. (2003). The combination of a potent vitamin D3 analog, EB 1089, with ionizing radiation reduces tumor growth and induces apoptosis of MCF-7 breast tumor xenografts in nude mice. Clin Cancer Res 9:2350–6
   Google Scholar
• Suzuki Y, Ichiyama T, Ohsaki A, et al. (2009). Anti-inflammatory effect of 1alpha,25-dihydroxyvitamin D(3) in human coronary arterial endothelial cells: Implication for the treatment of Kawasaki disease. J Steroid Biochem 113:134–8
   Google Scholar
• Swami S, Raghavachari N, Muller UR, et al. (2003). Vitamin D growth inhibition of breast cancer cells: Gene expression patterns assessed by cDNA microarray. Breast Cancer Res Treat 80:49–62
   PubMed Web of Science ®Google Scholar
• Swami S, Krishnan AV, Feldman D. (2011). Vitamin D metabolism and action in the prostate: Implications for health and disease. Mol Cell Endocrinol 5:61–9
   Google Scholar
• Switalska M, Nasulewicz-Goldeman A, Opolska A, et al. (2012). The in-vitro antiproliferative effect of PRI-2191 and imatinib applied in combined treatment with cisplatin, idarubicin, or docetaxel on human leukemia cells. Anticancer Drugs 23:70–80
   PubMedGoogle Scholar
• Széles L, Kresesztes G, Töröcsik D, et al. (2009). 1,25-Dihydroxyvitamin D3 is an autonomus regulator of the transcriptional changes leading to a tolerogenic dendritic cell phenotype. J Immunol 182:2074–83
   PubMed Web of Science ®Google Scholar
• Tałalaj M, Kapitan-Malinowska B, Debski K, et al. (2005). Administration of 1 alpha-OH vitamin D3 and calcium prevents bone mass loss in patients with advanced prostatic carcinoma after orchidectomy treated with complete androgenic blockade. Endokrynol Pol 56:225–32
   PubMedGoogle Scholar
• Tang JY, Fu T, Lau C, et al. (2012). Vitamin D in cutaneous carcinogenesis: Part II. J Am Acad Dermatol 67:817.e1–11, quiz 827–8
   Google Scholar
• Tang JY, Parimi N, Wu A, et al. (2010). Inverse association between serum 25(OH) vitamin D levels and non-melanoma skin cancer in elderly men. Cancer Causes Control 21:387–91
   PubMed Web of Science ®Google Scholar
• Tannour-Louet M, Lewis SK, Louet JF, et al. (2014). Increased expression of CYP24A1 correlates with advanced stages of prostate cancer and can cause resistance to vitamin D3-based therapies. FASEB J 28:364–72
   PubMedGoogle Scholar
• Tavera-Mendoza L, Wang TT, Lallemant B, et al. (2006). Convergence of vitamin D and retinoic acid signalling at a common hormone response element. EMBO Rep 7:180–5
   Google Scholar
• Teegarden D, Donkin SS. (2009). Vitamin D: Emerging new roles in insulin sensitivity. Nutr Res Rev 22:82–92
   PubMed Web of Science ®Google Scholar
• Thill M, Hoellen F, Becker S, et al. (2012). Expression of prostaglandin- and vitamin D-metabolising enzymes in benign and malignant breast cells. Anticancer Res 32:367–72
   PubMedGoogle Scholar
• Thill M, Fischer D, Kelling K, et al. (2010). Expression of vitamin D receptor (VDR), cyclooxygenase-2 (COX-2) and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in benign and malignant ovarian tissue and 25-hydroxycholecalciferol (25(OH2)D3) and prostaglandin E2 (PGE2) serum level in ovarian cancer patients. J Steroid Biochem Mol Biol 121:387–90
   PubMedGoogle Scholar
• Thorne JL, Maguire O, Doig CL. (2011). Epigenetic control of a VDR-governed feed-forward loop that regulates p21(waf1/cip1) expression and function in non-malignant prostate cells. Nucleic Acids Res 39:2045–56
   Google Scholar
• Ting HJ, Bao BY, Reeder JE, et al. (2007a). Increased expression of corepressors in aggressive androgen-independent prostate cancer cells results in loss of 1α,25-Dihydroxyvitamin D3 responsiveness. Mol Cancer Res 5:967–80
   PubMedGoogle Scholar
• Ting HJ, Hsu J, Bao BY, Lee YF. (2007b). Docetaxel-induced growth inhibition and apoptosis in androgen independent prostate cancer cells are enhanced by 1alpha,25-dihydroxyvitamin D3. Cancer Lett 247:122–9
   PubMedGoogle Scholar
• Ting HJ, Yasmin-Karim S, Yan SJ, et al. (2012). A positive feedback signaling loop between ATM and the vitamin D receptor is critical for cancer chemoprevention by vitamin D. Cancer Res 72:958–68
   Google Scholar
• Tiwari A. (2009). Elocalcitol, a vitamin D3 analog for the potential treatment of benign prostatic hyperplasia, overactive bladder and male infertility. Drugs 12:381–93
   PubMed Web of Science ®Google Scholar
• Tosetti F, Ferrari N, De Flora S, Albini A. (2002). ‘Angioprevention': Angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J 16:2–14
   PubMed Web of Science ®Google Scholar
• Tretli S, Hernes E, Berg JP, et al. (2009). Association between serum 25(OH)D and death from prostate cancer. Br J Cancer 100:450–4
   PubMed Web of Science ®Google Scholar
• Trouillas P, Honnorat J, Bret P, et al. (2001). Redifferentiation therapy in brain tumors: Long-lasting complete regression of glioblastomas and an anaplastic astrocytoma under long term 1-alpha-hydroxycholecalciferol. J Neurooncol 51:57–66
   PubMed Web of Science ®Google Scholar
• Trump DL, Deeb KK, Johnson CS. (2010). Vitamin D: Considerations in the continued development as an agent for cancer prevention and therapy. Cancer J 16:1–9
   PubMed Web of Science ®Google Scholar
• Tse AK, Zhu GY, Wan CK, et al. (2010). 1Alpha,25-Dihydroxyvitamin D3 inhibits transcriptional potential of nuclear factor kappa B in breast cancer cells. Mol Immunol 47:1728–38
   PubMedGoogle Scholar
• Tu H, Flanders WD, Ahearn TU, et al. (2013). Effects of calcium and vitamin D3 on transforming growth factors in rectal mucosa of sporadic colorectal adenoma patients: A randomized controlled trial. Mol Carcinog. [Epub ahead of print]. doi:10.1002/mc.22096
   Google Scholar
• Urbschat A, Paulus P, von Quernheim QF, et al. (2013). Vitamin D hydroxylases CYP2R1, CYP27B1 and CYP24A1 in renal cell carcinoma. Eur J Clin Invest 43:1282–90
   PubMed Web of Science ®Google Scholar
• Unten S, Ishihara M, Sakagami H. (2004). Relationship between differentiation-inducing activity and hypercalcemic activity of hexafluorotrihydroxyvitamin D3 derivatives. Anticancer Res 24:683–9
   PubMedGoogle Scholar
• Valko M, Rhodes CJ, Moncol J, Izakovic MM. (2006). Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 160:1–40
   PubMed Web of Science ®Google Scholar
• Valrance ME, Brunet AH, Welsh J. (2007). Vitamin D receptor-dependent inhibition of mammary tumor growth by EB1089 and ultraviolet radiation in vivo. Endocrinology 148:4887–94
   PubMed Web of Science ®Google Scholar
• van den Bemd GJ, Chang GT. (2002). Vitamin D and vitamin D analogs in cancer treatment. Curr Drug Targets 3:85–94
   PubMed Web of Science ®Google Scholar
• van Driel M, Koedam M, Buurman CJ, et al. (2006). Evidence that both 1alpha,25-dihydroxyvitamin D3 and 24-hydroxylated D3 enhance human osteoblast differentiation and mineralization. J Cell Biochem 99:922–35
   PubMed Web of Science ®Google Scholar
• van Ginkel PR, Yang W, Marcet MM, et al. (2007). 1Alpha-hydroxyvitamin D2 inhibits growth of human neuroblastoma. J Neurooncol 85:255–62
   PubMedGoogle Scholar
• Vanoirbeek E, Krishnan A, Eelen G, et al. (2011). The anti-cancer and anti-inflammatory actions of 1,25(OH)D. Best Pract Res Clin Endocrinol Metab 25:593–604
   PubMed Web of Science ®Google Scholar
• VanWeelden K, Flanagan L, Binderup L, et al. (1998). Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D3 analog, EB1089. Endocrinology 139:2102–10
   PubMed Web of Science ®Google Scholar
• Verlinden L, Verstuyf A, Convents R, et al. (1998). Action of 1,25(OH)2D3 on the cell cycle genes, cyclin D1, p21 and p27 in MCF-7 cells. Mol Cell Endocrinol 142:57–65
   PubMed Web of Science ®Google Scholar
• Verlinden L, Verstuyf A, Van Camp M, et al. (2000). Two novel 14-epi-analogues of 1,25-dihydroxyvitamin D3 inhibit the growth of human breast cancer cells in vitro and in vivo. Cancer Res 60:2673–9
   PubMed Web of Science ®Google Scholar
• Vuolo L, Di Somma C, Faggiano A, Colao A. (2012). Vitamin D and cancer. Front Endocrinol 3:58. doi:10.3389/fendo.2012.00058
   PubMedGoogle Scholar
• Wactawski-Wende J, Kotchen JM, Anderson GL, et al. (2006). Women's Health Initiative Investigators Calcium plus vitamin D supplementation and the risk of colorectal cancer. New Eng J Med 354:684–96
   PubMed Web of Science ®Google Scholar
• Wahler J, So JY, Kim YC, et al. (2014). Inhibition of the transition of ductal carcinoma in situ to invasive ductal carcinoma by a Gemini vitamin D analog. Cancer Prev Res (Phila) 7:617–26
   PubMedGoogle Scholar
• Wang D, Dubois RN. (2010). Eicosanoids and cancer. Nat Rev Cancer 10:181–93
   PubMed Web of Science ®Google Scholar
• Wang J, Lian H, Zhao Y, et al. (2008). Vitamin D3 induces autophagy of human myeloid leukemia cells. J Biol Chem 12:25596–605
   Google Scholar
• Wang QM, Jones JB, Studzinski GP. (1996). Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells. Cancer Res 56:264–7
   PubMed Web of Science ®Google Scholar
• Wang TT, Nestel FP, Bourdeau V, et al. (2004). Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 173:2909–12
   PubMed Web of Science ®Google Scholar
• Wang TT, Dabbas B, Laperriere D, et al. (2010a). Direct and indirect induction by 1,25-dihydroxyvitamin D3 of the NOD2/CARD15-defensin beta2 innate immune pathway defective in Crohn disease. J Biol Chem 285:2227–31
   PubMed Web of Science ®Google Scholar
• Wang X, Chen W, Singh N, et al. (2010b). Effects of potential calcium sensing receptor inducers on promoting chemosensitivity of human colon carcinoma cells. Int J Oncol 36:1573–80
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhu J, DeLuca HF. (2012). Where is the vitamin D receptor? Arch Biochem Biophys 523:123–33.
   PubMed Web of Science ®Google Scholar
• Wang X, Studzinski GP. (1997). Antiapoptotic action of 1,25-dihydroxyvitamin D3 is associated with increased mitochondrial MCL-1 and RAF-1 proteins and reduced release of cytochrome c. Exp Cell Res 235:210–17
   PubMed Web of Science ®Google Scholar
• Welsh J. (2012). Cellular and molecular effects of vitamin D on carcinogenesis. Arch Biochem Biophys 523:107–14
   PubMed Web of Science ®Google Scholar
• Wietrzyk J, Peczyska M, Madej J, et al. (2004). Toxicity and antineoplastic effect of (24R)-1,24-dihydroxyvitamin D3 (PRI2191). Steroids 69:629–35
   PubMedGoogle Scholar
• Wigington DP, Urben CM, Strugnell SA, Knutson JC. (2004). Combination study of 1,24(S)-dihydroxyvitamin D2 and chemotherapeutic agents on human breast and prostate cancer cell lines. Anticancer Res 24:2905–12
   PubMedGoogle Scholar
• Woeckel VJ, van der Eerden BC, Schreuders-Koedam M, et al. (2013). 1α,25-Dihydroxyvitamin D3 stimulates activin A production to fine-tune osteoblast-induced mineralization. J Cell Physiol 228:2167–74
   PubMedGoogle Scholar
• Woolcott CG, Wilkens LR, Nomura AM, et al. (2010). Plasma 25-hydroxyvitamin D levels and the risk of colorectal cancer: The multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 19:130–4
   PubMed Web of Science ®Google Scholar
• Wu G, Fan RS, Li W, et al. (1998). Regulation of transforming growth factor-beta type II receptor expression in human breast cancer MCF-7 cells by vitamin D3 and its analogues. J Biol Chem 273:7749–56
   PubMedGoogle Scholar
• Wu RY, Zhang Y, Feng XH, Derynck R. (1997a). Homomeric and heteromeric interactions are required for signaling activity and functional cooperativity of Smad-3 and -4. Mol Cell Biol 17:2521–8
   PubMedGoogle Scholar
• Wu S, Sun J. (2011). Vitamin D, vitamin D receptor, and macroautophagy in inflammation and infection. Discov Med 11:325–35
   PubMed Web of Science ®Google Scholar
• Wu Y, Haugen JD, Zinsmeister AR, Kumar R. (1997b). 1Alpha,25-dihydroxyvitamin D3 increases transforming growth factor and transforming growth factor receptor type I and II synthesis in human bone cells. Biochem Biophys Res Commun 239:734–9
   PubMedGoogle Scholar
• Xiao W, Hodge DR, Wang L, et al. (2004). Co-operative functions between nuclear factors NFκB and CCAT/enhancer-binding protein-β (C/EBP-β) regulate the IL-6 promoter in autocrine human prostate cancer cells. Prostate 61:354–70
   PubMedGoogle Scholar
• Xu H, Posner GH, Stevenson M, Campbell FC. (2010). Apc(MIN) modulation of vitamin D secosteroid growth control. Carcinogenesis 31:1434–41
   PubMedGoogle Scholar
• Xu J, Li W, Ma J, et al. (2013). Vitamin D pivotal nutraceutical in the regulation of cancer metastasis and angiogenesis. Curr Med Chem 20:4109–20
   PubMedGoogle Scholar
• Yanagisawa J, Yanagi Y, Masuhiro Y, et al. (1999). Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators. Science 26:1317–21
   Google Scholar
• Yang ES, Burnstein KL. (2003). Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm. J Biol Chem 278:46862–8
   PubMed Web of Science ®Google Scholar
• Yang L, Yang J, Venkateswarlu S, et al. (2001). Autocrine TGFbeta signaling mediates vitamin D3 analog-induced growth inhibition in breast cells. J Cell Physiol 188:383–93
   PubMedGoogle Scholar
• Yao S, Ambrosone CB. (2013). Associations between vitamin D deficiency and risk of aggressive breast cancer in African-American women. J Steroid Biochem Mol Biol 136:337–41
   PubMedGoogle Scholar
• Young MR, Day TA. (2013). Immune regulatory activity of vitamin D3 in head and neck cancer. Cancers (Basel) 5:1072–85
   PubMedGoogle Scholar
• Yuan L, Jiang R, Yang Y, et al. (2012). 1,25-Dihydroxyvitamin D3 inhibits growth of the breast cancer cell line MCF-7 and downregulates cytochrome P4501B1 through the COX-2/PGE2 pathway. Oncol Rep 28:2131–7
   PubMedGoogle Scholar
• Zehnder D, Bland R, Chana RS, et al. (2002). Synthesis of 1,25-dihydroxyvitamin D(3) by human endothelial cells is regulated by inflammatory cytokines: A novel autocrine determinant of vascular cell adhesion. J Am Soc Nephrol 13:621–9
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang H, Zhang X, Yu Z. (2013). Synergistic effect of retinoic acid and vitamin D analog EB1089-induced apoptosis of hepatocellular cancer cells. Cytotechnology 65:457–65
   PubMedGoogle Scholar
• Zhang X, Li P, Bao J, et al. (2005). Suppression of death receptor-mediated apoptosis by 1,25-dihydroxyvitamin D3 revealed by microarray analysis. J Biol Chem 280:35458–68
   PubMedGoogle Scholar
• Zhang Y, Guo Q, Zhang Z, et al. (2014). VDR status arbitrates the prometastatic effects of tumor-associated macrophages. Mol Cancer Res 12:1181–91
   PubMedGoogle Scholar
• Zhang Z, Kovalenko P, Cui M, et al. (2010). Constitutive activation of the mitogen-activated protein kinase pathway impairs vitamin D signaling in human prostate epithelial cells. J Cell Physiol 224:433–42
   PubMedGoogle Scholar
• Zhao XY, Ly LH, Peehl DM, Feldman D. (1997). 1Alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent. Endocrinology 138:3290–8
   PubMed Web of Science ®Google Scholar
• Zhou S, LeBoff MS, Glowacki J. (2010). Vitamin D metabolism and action in human bone marrow stromal cells. Endocrinology 151:14–22
   PubMed Web of Science ®Google Scholar
• Zhuang SH, Burnstein KL. (1998). Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 139:1197–207
   PubMed Web of Science ®Google Scholar
• Zhuang SH, Schwartz GG, Cameron D, Burnstein KL. (1997). Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines. Mol Cell Endocrinol 126:83–90
   PubMed Web of Science ®Google Scholar